BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31987649)

  • 1. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study.
    Bolm L; Ohrner K; Nappo G; Rückert F; Zimmermann C; Rau BM; Petrova E; Honselmann KC; Lapshyn H; Bausch D; Weitz J; Sandini M; Keck T; Zerbi A; Distler M; Wellner UF
    Pancreatology; 2020 Apr; 20(3):433-441. PubMed ID: 31987649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
    Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
    Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
    JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
    Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
    Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
    Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
    Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.
    Kim WS; Choi DW; Choi SH; Heo JS; You DD; Lee HG
    J Surg Oncol; 2012 Mar; 105(3):266-72. PubMed ID: 21882202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study.
    Moekotte AL; Lof S; Van Roessel S; Fontana M; Dreyer S; Shablak A; Casciani F; Mavroeidis VK; Robinson S; Khalil K; Gradinariu G; Mowbray N; Al-Sarireh B; Fusai GK; Roberts K; White S; Soonawalla Z; Jamieson NB; Salvia R; Besselink MG; Abu Hilal M
    Ann Surg; 2020 Dec; 272(6):1086-1093. PubMed ID: 30628913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas.
    Lee JH; Whittington R; Williams NN; Berry MF; Vaughn DJ; Haller DG; Rosato EF
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):945-53. PubMed ID: 10863064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: A retrospective study of 5-year survivors.
    El Nakeeb A; El Sorogy M; Ezzat H; Said R; El Dosoky M; Abd El Gawad M; Elsabagh AM; El Hanafy E
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):443-449. PubMed ID: 30126828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
    Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
    J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses.
    Lai ZW; Bolm L; Fuellgraf H; Biniossek ML; Makowiec F; Hopt UT; Werner M; Keck T; Bausch D; Sorio C; Scarpa A; Schilling O; Bronsert P; Wellner UF
    BMC Cancer; 2016 Mar; 16():195. PubMed ID: 26951071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy.
    Bowitz Lothe IM; Kleive D; Pomianowska E; Cvancarova M; Kure E; Dueland S; Gladhaug IP; Labori KJ
    Pancreatology; 2019 Mar; 19(2):316-324. PubMed ID: 30713128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.
    Petrou A; Soonawalla Z; Silva MA; Manzelli A; Moris D; Tabet PP; Friend P
    J BUON; 2016; 21(4):874-882. PubMed ID: 27685908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of Intra-Ampullary Papillary-Tubular Neoplasm versus Flat Dysplasia as Precursor Lesions of Ampullary Adenocarcinoma.
    Han S; Jang KT; Choi DW; Choi SH; Heo JS; Han IW; Park D; Ryu Y
    Dig Surg; 2020; 37(6):505-514. PubMed ID: 33080609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
    Showalter TN; Zhan T; Anne PR; Chervoneva I; Mitchell EP; Yeo CJ; Rosato EL; Kennedy EP; Berger AC
    J Gastrointest Surg; 2011 Aug; 15(8):1411-6. PubMed ID: 21523621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and pathological features of pancreatic, ampullary, biliary and duodenal cancers resected with pancreaticoduodenectomy.
    Chandrasegaram MD; Chiam SC; Chen JW; Khalid A; Mittinty ML; Neo EL; Tan CP; Dolan PM; Brooke-Smith ME; Kanhere H; Worthley CS
    World J Surg Oncol; 2015 Feb; 13():85. PubMed ID: 25890023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the two histological subtypes of ampullary adenocarcinoma: a retrospective study.
    Xu ZY; Guan J; Zhang ZY; Liu DW; Li XD; Zhou ZQ
    Cir Cir; 2024; 92(2):159-164. PubMed ID: 38782386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
    Krishnan S; Rana V; Evans DB; Varadhachary G; Das P; Bhatia S; Delclos ME; Janjan NA; Wolff RA; Crane CH; Pisters PW
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):735-43. PubMed ID: 17980502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of the posterior resection margin for predicting disease free survival in ampullary adenocarcinoma.
    Schneider C; Sodergren MH; Pencavel T; Soggiu F; Bhogal RH; Khan AZ
    Surg Oncol; 2020 Dec; 35():211-217. PubMed ID: 32911213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?
    Westgaard A; Pomianowska E; Clausen OP; Gladhaug IP
    Ann Surg Oncol; 2013 Feb; 20(2):430-9. PubMed ID: 22956064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.